

Fund Profile:

Nucleus Wealth Australian Leaders

23-27

| Features | |
|-------------------|--|
| Number of stocks: | |
| Danahasadu | |

Benchmark: ASX 20 Hedging: None Target Cash: 1.0% Maximum Cash: 5.0%

Suggested Minimums1:

- Initial Investment- Additional deposits- Time Invested\$10,000\$15 years

Fees:

| - Investment fee | 0.17% |
|------------------------|-------|
| - Indirect Cost Ratio2 | 0.00% |
| - Performance Fee | None |

Investor Suitability

Investors who have a high tolerance for risk and a long term investment timeframe.

Risk Levels

Very High. Negative return 6 years in every 20 years.

Available as a Separately Managed Account on the following platforms:


Praemium, Interactive Brokers

Investment Objective

This is a passive strategy designed to provide a (gross of fees) return in line with the S&P/ASX 20 Accumulation Index over rolling five year periods.

| Return to 30 Apr 2025 | 1m | 3m | 1у | 3у | Incept. |
|-----------------------------------|-----|------|------|--------|---------|
| | % | % | % | % p.a. | % p.a.4 |
| Nucleus Wealth Australian Leaders | | | | | |
| - Pre fees | 3.8 | -4.2 | 10.5 | 7.6 | 10.0 |
| - Post investment fees | 3.8 | -4.4 | 10.1 | 7.3 | 9.7 |
| Investment Objective: | | | • | • | |
| - ASX 20 | 4.0 | -3.6 | 10.1 | 8.0 | 10.0 |

Cumulative Returns



Investment Strategy

The model provides exposure to a portfolio of the 25 largest companies on the ASX. Securities are selected using a rules-based approach.

- 1. Portfolios with low balances may deviate performance due to share parcel sizes. 2. Based on strategic asset position. May be higher/lower based on tactical positions.
- 3. Administration fees vary on account type, amount invested and platform used. See PDS for details. 4. Inception is 30 Dec 2020.

The information on this page contains general information and does not take into account your personal objectives, financial situation or needs. Past performance is not an indication of future performance. Nucleus Wealth Management is a Corporate Authorised Representative of Nucleus Advice Pty Ltd - AFSL 515796.